---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-005668"
form_type: "8-K"
ticker: "PAYS"
cik: "0001496443"
company_name: "Paysign, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:37:14.333397+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Paysign Q2 revenue $19.08M (+33%), net income $1.39M (+99%), raises FY2025 guidance

## Summary
- Q2 revenue $19.08M (+33.1% YoY), net income $1.39M (+99.1%), diluted EPS $0.02; Adj. EBITDA $4.51M (+101.8%), $0.08 per share.
- Pharma patient affordability revenue surged 189.9% to 40.6% of total; added 7 net programs, now 97 active.
- Added 123 net plasma centers in Q2, exiting with 607; plasma revenue down 4.7% due to industry oversupply.
- FY2025 guidance raised: revenue $76.5-78.5M, net income $6-7M ($0.10-0.12 diluted EPS), Adj. EBITDA $18-20M.
- Q3 2025 guidance: revenue $19.5-20.5M, gross margin ~59%, Adj. EBITDA $4.5-5.0M.

## SEC filing metadata
- accession: 0001683168-25-005668
- form_type: 8-K
- ticker: PAYS
- cik: 0001496443
- company_name: Paysign, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496443/000168316825005668/0001683168-25-005668-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496443/000168316825005668/paysign_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-005668
- JSON: https://secwatch.observer/filing/0001683168-25-005668.json
- Plain text: https://secwatch.observer/filing/0001683168-25-005668.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.